Replies to post #4817 on Halozyme Therapeutics Inc (HALO)

[maumar]

June 26, 2017. I don't know if Mabthera SC will be approved for all indications. If so, royalty potential is approximately $150M. I don't think this is priced in and I look forward to analysts adjusting estimates. We can also expect Herceptin SC in the US in 2018. If I did not have a huge position already I would buy today.